Metsera eyes $289M IPO to fund phase 3 weight loss trial
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. | Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist.
Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.
Monday saw the release of JMP Securities' latest industry overview for the biotechnology sector, which highlighted key events from January 2025. The report noted a modest resurgence in the sector, ...
Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...
Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...
Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...
Recent health news covers significant events like Pfizer's diversity program settlement, AstraZeneca's halted UK investment, ...
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
By Prakhar Srivastava (Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 ...
Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback